Trial reportFrontiers in oncology2026
Preemptive analgesia with parecoxib sodium alleviates short-term pain after endoscopic submucosal dissection for early esophageal cancer and precancerous lesions: a single-center, double-arm, and randomized controlled study.
Trial report in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Endoscopic submucosal dissection (ESD) is the preferred treatment for early esophageal cancer and precancerous lesions. Postoperative pain is a prevalent but often overlooked issue.This study investigated the analgesic efficacy and safety of preemptive parecoxib sodium in patients undergoing ESD for early esophageal cancer and precancerous lesions. Methods: Patients scheduled for ESD under general anesthesia were enrolled and randomly allocated to the medication group (intravenous parecoxib sodium 30 minutes prior to surgery) or the control group (4 mL intravenous normal saline 30 minutes before the procedure). Clinical data, including perioperative serum levels of high-sensitivity C-reactive protein, IL-6, complete blood count, and biochemical parameters, were collected. Postoperative pain intensity was assessed using the visual analog scale (VAS) at 6, 12, 24, 72, and 120 hours after the procedure. Results: A total of 78 patients participated (40 in the parecoxib group, 38 in the control group). The two groups were comparable in baseline characteristics and preoperative inflammatory/nutritional indicators (all P > 0.05). At 6 and 12 hours post-operation, pain scores in the medication group were significantly lower than those in the control group (P < 0.05), while VAS scores at 24, 72, and 120 hours showed no significant differences between groups (P > 0.05). The frequency and total dosage of postoperative tramadol administration, as well as the incidence of adverse reactions, were comparable between the two groups (all P > 0.05). Conclusion: Preemptive analgesia with parecoxib sodium can alleviate early postoperative pain in patients with early esophageal cancer and precancerous lesions who undergo ESD for mucosal defects involving less than three-quarters of the esophageal circumference, without increasing adverse reactions or the subsequent use of analgesic drugs. Clinical trial registration: https://www.chictr.org.cn/showproj.html?proj=218572, identifier ChiCTR2400080433.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.